EDIT News and Press, Editas Medicine Inc.

Riskified Ltd. Class A (RSKD) is expected to report $0.02 for Q4 2025 SunOpta Inc. (STKL) is expected to report $0.05 for Q4 2025 One Liberty Properties Inc. (OLP) is expected to report $0.41 for Q4 2025 Tourmaline Oil Corp (TRMLF) is expected to report $0.35 for Q4 2025 StubHub H...

2026-01-28 08:05:23 ET Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine DENVER, Colo – CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine ...

2025-11-10 07:19:56 ET More on Editas Medicine Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar Call Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar...

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial ...

VEON Ltd. (VEON) is expected to report $1.21 for Q3 2025 eToro Group Ltd. (ETOR) is expected to report $0.52 for Q3 2025 KE Holdings Inc American Depositary Shares (each representing three Class A) (BEKE) is expected to report $0.09 for Q3 2025 CoreWeave Inc. (CRWV) is expected to rep...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association ...

Hess Midstream LP Class A Representing Limited Partner Interests (HESM) is expected to report $0.73 for Q3 2025 IDEAYA Biosciences Inc. (IDYA) is expected to report $0 for Q3 2025 Unum Group (UNM) is expected to report $2.15 for Q3 2025 CNA Financial Corporation (CNA) is expected to r...

2025-10-31 12:14:01 ET More on CRISPR Therapeutics Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook Crispr: Investors Waiting Patiently For In-Vivo Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now ...

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6 billion by 2033, with institutional investors pouring capital i...

2025-10-14 18:18:10 ET Gene editing seems easy! It is exactly what it sounds like. Identify a part of the gene that isn’t right (i.e., mutated). Delete it. And go from there. Or perhaps you add something else to replace what you delete. It’s analogous to editing wr...